论文部分内容阅读
目的探讨糖尿病肾病大鼠胰岛及肾脏骨钙素(BGP)表达的情况及厄贝沙坦对胰岛及肾脏骨钙素表达的影响。方法选择36只SD雄性大鼠给予链脲佐菌素(30 mg/kg)造糖尿病大鼠模型,随机分成糖尿病对照组(DM组)、50 mg/kg厄贝沙坦组(I组),另选取同龄大鼠作为正常对照组(NC组)。造模后采用灌胃法给药8周;ELISA法检测24 h尿白蛋白排泄率;图像分析测定胰腺及肾小球BGP。结果药物干预组的24 h尿白蛋白排泄率显著降低,BGP在胰腺的表达明显增多,而在肾脏的表达明显减少。结论骨骼分泌的骨钙素在胰岛细胞及肾脏呈阳性,提示其可能参与糖代谢及肾脏损害。厄贝沙坦治疗后肾脏骨钙素水平下降,提示其可能减少骨钙素在肾脏的沉积,改善肾功能,但机制有待证实。
Objective To investigate the expression of BGP in pancreatic islets and kidneys of diabetic nephropathy rats and the effect of irbesartan on the expression of osteocalcin in islets and kidneys. Methods Thirty-six male Sprague-Dawley rats were randomly divided into diabetes control group (DM group), 50 mg / kg irbesartan group (group I), diabetic rat model with streptozotocin (30 mg / kg) The same age rats were selected as normal control group (NC group). Gavage method was used to establish the model for 8 weeks after administration. The urinary albumin excretion rate was measured by ELISA and the pancreatic and glomerular BGP were detected by image analysis. Results The 24 h urinary albumin excretion rate was significantly decreased in the drug-treated group. The expression of BGP in the pancreas was significantly increased, while the expression in the kidney was significantly reduced. Conclusion The skeletal-derived osteocalcin is positive in islet cells and kidneys, suggesting that it may be involved in glucose metabolism and kidney damage. Irbesartan renal osteocalcin levels after treatment decreased, suggesting that it may reduce the deposition of osteocalcin in the kidneys and improve renal function, but the mechanism remains to be confirmed.